icotinib

Key facts

Mechanism of action

Epidermal growth factor receptor erbB1 inhibitor

Primary target: Epidermal growth factor receptor

Approval history

1. Icotinib Phase 2 · First People's Hospital · Esophageal Cancer
2. Icotinib Phase 2 · First People's Hospital · Non-Small Cell Lung Cancer
3. 1% icotinib hydrochloride cream Phase 1 · Betta Pharmaceuticals Co · Psoriasis
4. Sequential Icotinib Plus Chemotherapy Approved · Betta Pharmaceuticals Co · EGFR Positive Non-small Cell Lung Cancer

1. erlotinib hydrochloride Epidermal growth factor receptor erbB1 inhibitor
2. lapatinib ditosylate Receptor protein-tyrosine kinase erbB-2 inhibitor
3. mobocertinib Antineoplastic and immunomodulating agents (L01)
4. mobocertinib succinate Epidermal growth factor receptor erbB1 inhibitor
5. neratinib maleate Receptor protein-tyrosine kinase erbB-2 inhibitor
6. afatinib dimaleate Epidermal growth factor receptor erbB1 inhibitor

Frequently asked questions